Tarsa Completes Phase III For Oral Calcitonin In Osteoporosis, Plans 2011 NDA
Initially, biotech will pursue a treatment indication but also has its recombinant oral formulation in Phase II for osteoporosis prevention.
Initially, biotech will pursue a treatment indication but also has its recombinant oral formulation in Phase II for osteoporosis prevention.